Neurodegenerative diseases are a broad collection of diseases, which are all characterized by loss of neuronal function. That includes (but not limited to) Alzheimer's disease, frontotemporal dementia, and Parkinson's disease to which biomarkers will be described on the below page. One of the primary goals is to identify active neurodegeneration and find out if treatment will halt or slow that process. Our biomarkers can do that.
More about our biomarkers for Alzheimers
Multiple Sclerosis is the most common disabling neuroinflammatory disease of young adults and is known as a chronic autoimmune disease, where inflammatory demyelination and neurodegeneration occur in CNS. Quantifying disease activity in multiple sclerosis provides a unique insight into structural lesions and functional changes in the disease pathogenesis.
More about our biomarkers for multiple sclerosis
In a healthy brain, α-synuclein supports neuronal communication. However, in Parkinson’s, this protein undergoes abnormal processing, driven partly by the enzyme Calpain-1, which cleaves α-synuclein into smaller, altered fragments. This early cleavage disrupts cellular function and promotes the formation of toxic aggregates, which accumulate, kill neurons, and drive disease progression.
Search and find publications that we have published.
Please don't hesitate to contact us if you have any questions or other inquiries.
